Endurx Pharmaceuticals Inc

Chemotherapy for treatment of cancer still relies on delivering a highly-toxic drug throughout the entire body. Although little of the administered drug actually reaches the tumor, the adverse side effects can be horrific. Our novel delivery system rapidly transports drug to the tumor microenvironment This rapid transport and high specificity of delivery can improve the effectiveness of the drug while greatly reducing adverse side effects. Promising data was obtained in mouse models of triple-negative breast cancer and glioblastoma, two hard-to-treat cancers with poor prognosis for patients. EnduRx is advancing the delivery system into IND-enabling activities with efficacy in human subjects in 3-4 years. Application of the delivery system to formulation of approved or developmental drugs offers improved effectiveness and better patient experience, and could provide patent life extension.